Infant Bacterial Therapeutics AB (publ)의 주요 재무제표는 무엇인가요?
IFTBF의 주요 재무 비율은 무엇인가요?
Infant Bacterial Therapeutics AB (publ)의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Infant Bacterial Therapeutics AB (publ)은 수익성이 있나요?
Infant Bacterial Therapeutics AB (publ)에 부채가 있나요?
Infant Bacterial Therapeutics AB (publ)의 발행 주식은 몇 주인가요?
주요 통계
이전 종가
$4.78
시가
$5.47
일일 범위
$5.47 - $5.47
52주 범위
$4.78 - $8.2
거래량
--
평균 거래량
1.0K
EPS(TTM)
--
배당수익률
--
시가총액
--
INFANT BACTERIAL THERAPEUTICS A란 무엇인가요?
Infant Bacterial Therapeutics AB is a clinical stage pharmaceutical company, which engages in the development of drugs for the treatment of rare diseases affecting premature infants. The company is headquartered in Stockholm, Stockholm and currently employs 10 full-time employees. The company went IPO on 2016-03-29. The firm develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.